Aminothiazole derivative
    1.
    发明授权
    Aminothiazole derivative 失效
    氨基噻唑衍生物

    公开(公告)号:US08637557B2

    公开(公告)日:2014-01-28

    申请号:US13502636

    申请日:2010-10-04

    CPC分类号: C07D417/04 C07D417/14

    摘要: A compound represented by formula (1) or a pharmaceutically acceptable salt thereof, which has a PI3 kinase γ inhibitory effect and is useful as a prophylactic or therapeutic agent for articular rheumatism, Crohn's disease, irritable colitis, Sjoegren's syndrome, multiple sclerosis, systemic lupus erythematosus, asthma, atopic dermatitis, arteriosclerosis, organ transplant rejection, cancer, retinopathy, psoriasis, arthrosis deformans, age-related macular degeneration, type II diabetes, insulin resistance, obesity, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), hyperlipemia, etc.

    摘要翻译: 由式(1)表示的化合物或其药学上可接受的盐,其具有PI3激酶γ抑制作用,并且可用作关节风湿病,克罗恩病,过敏性结肠炎,Sjoegren综合征,多发性硬化症,系统性狼疮的预防或治疗剂 红斑狼疮,哮喘,特应性皮炎,动脉硬化,器官移植排斥,癌症,视网膜病变,牛皮癣,变形性关节炎,年龄相关性黄斑变性,II型糖尿病,胰岛素抵抗,肥胖,非酒精性脂肪性肝病(NAFLD),非酒精性 脂肪性肝炎(NASH),高脂血症等

    Cyclic amine compound
    5.
    发明授权
    Cyclic amine compound 失效
    环胺化合物

    公开(公告)号:US07601734B2

    公开(公告)日:2009-10-13

    申请号:US11578169

    申请日:2005-04-08

    IPC分类号: A61K31/44 A61P25/18 A61P25/24

    摘要: An object of the present invention is to provide a cyclic amine compound which has a potent inhibitory effect on the binding of α2C-adrenoceptor and is useful in preventing and treating disorders attributable to α2C-adrenoceptor.The above-described object is solved by the following cyclic amine compound, etc., wherein X is O, S, SO, SO2 or NR2, etc.; R1 is a hydrogen atom, a cyano group, a carboxyl group, a C2-C13 alkoxycarbonyl group, a carbamoyl group, etc.; Ar1 and Ar2 are the same or different and each represent an aryl or heteroaryl group which may be substituted by 1 to 3 substituents and so on; ring B is a benzene ring may be substituted by 1 to 3 substituents and so on; n is an integer from 1 to 10; and p and q are the same or different and each represent an integer of 1 or 2.

    摘要翻译: 本发明的目的是提供对α2C-肾上腺素能受体的结合具有强效抑制作用的环胺化合物,可用于预防和治疗归因于α2C-肾上腺素受体的病症。 上述目的通过以下环胺化合物等来解决,其中X是O,S,SO,SO 2或NR 2等; R1是氢原子,氰基,羧基,C2-C13烷氧基羰基,氨基甲酰基等; Ar 1和Ar 2相同或不同,各自表示可被1〜3个取代基等取代的芳基或杂芳基; 环B为苯环可被1〜3个取代基取代等; n是1至10的整数; p和q相同或不同,各自表示1或2的整数。

    Cyclic Amine Compound
    7.
    发明申请
    Cyclic Amine Compound 失效
    环胺化合物

    公开(公告)号:US20070244145A1

    公开(公告)日:2007-10-18

    申请号:US11578169

    申请日:2005-04-08

    IPC分类号: A61K31/44 A61P25/18 A61P25/24

    摘要: An object of the present invention is to provide a cyclic amine compound which has a potent inhibitory effect on the binding of α2C-adrenoceptor and is useful in preventing and treating disorders attributable to α2C-adrenoceptor. The above-described object is solved by the following cyclic amine compound, etc., wherein X is O, S, SO, SO2 or NR2, etc.; R1 is a hydrogen atom, a cyano group, a carboxyl group, a C2-C13 alkoxycarbonyl group, a carbamoyl group, etc.; Ar1 and Ar2 are the same or different and each represent an aryl or heteroaryl group which may be substituted by 1 to 3 substituents and so on; ring B is a benzene ring may be substituted by 1 to 3 substituents and so on; n is an integer from 1 to 10; and p and q are the same or different and each represent an integer of 1 or 2.

    摘要翻译: 本发明的目的是提供对α2C-肾上腺素能受体的结合具有强效抑制作用的环胺化合物,可用于预防和治疗归因于α2C-肾上腺素受体的病症。 上述目的通过以下环胺化合物等来解决,其中X是O,S,SO,SO 2或NR 2等; R 1是氢原子,氰基,羧基,C 1 -C 13烷氧基羰基,氨基甲酰基等 。 Ar 1和Ar 2相同或不同,各自表示可被1至3个取代基等取代的芳基或杂芳基; 环B为苯环可被1〜3个取代基取代等; n是1至10的整数; p和q相同或不同,各自表示1或2的整数。

    1,3-Dihydro-2h-indol-2-one derivative
    8.
    发明申请
    1,3-Dihydro-2h-indol-2-one derivative 失效
    1,3-二氢-2H-吲哚-2-酮衍生物

    公开(公告)号:US20060276449A1

    公开(公告)日:2006-12-07

    申请号:US10569833

    申请日:2004-08-27

    CPC分类号: C07D403/04

    摘要: A 1,3-dihydro-2H-indol-2-one derivative expressed by Formula 1 (wherein R1 is a halogen atom, a C1 to C4 alkyl group, etc., and R2 is a hydrogen atom, a halogen atom, etc., or R2 is in the 6-position of the indol-2-one and R1 and R2 join together to form a C3 to C6 alkylene group, R3 is a halogen atom, a hydroxyl group, etc., and R4 is a hydrogen atom, a halogen atom, a C1 to C4 alkyl group, etc., or R4 is in the 3-position of the phenyl and R3 and R4 join together to form a methylenedioxy group, R5 is a hydrogen atom or a fluorine atom, R6 is an ethylamino group, a dimethylamino group, etc., R7 is a C1 to C4 alkoxy group, and R8 is a C1 to C4 alkoxy group), or a pharmaceutically acceptable salt of this derivative. This is a novel compound that has antagonistic activity against an aruginine-vasopressin V1b receptor.

    摘要翻译: 由式1表示的1,3-二氢-2H-吲哚-2-酮衍生物(其中R 1是卤素原子,C 1至C 1烷基, 4个烷基等,R 2是氢原子,卤原子等,或R 2 2位在6位的 吲哚-2-酮和R 1和R 2连接在一起以形成C 6 -C 6亚烷基, 亚烷基,R 3是卤素原子,羟基等,R 4是氢原子,卤原子,C 1, / SUB→C 4烷基等,或R 4在苯基的3位和R 3和R 3 连接在一起形成亚甲二氧基,R 5是氢原子或氟原子,R 6是乙氨基,二甲基氨基 基团等,R 7是C 1-4烷氧基的C 1至C 8,并且R 8是 C 1至C 4烷氧基),或该衍生物的药学上可接受的盐。 这是一种新的化合物,具有对抗葡萄糖酸加压素V1b受体的拮抗作用。

    1,3-dihydro-2H-indol-2-one derivative
    10.
    发明授权
    1,3-dihydro-2H-indol-2-one derivative 失效
    1,3-二氢-2H-吲哚-2-酮衍生物

    公开(公告)号:US07528124B2

    公开(公告)日:2009-05-05

    申请号:US10569833

    申请日:2004-08-27

    CPC分类号: C07D403/04

    摘要: A 1,3-dihydro-2H-indol-2-one derivative expressed by Formula 1 (wherein R1 is a halogen atom, a C1 to C4 alkyl group, etc., and R2 is a hydrogen atom, a halogen atom, etc., or R2 is in the 6-position of the indol-2-one and R1 and R2 join together to form a C3 to C6 alkylene group, R3 is a halogen atom, a hydroxyl group, etc., and R4 is a hydrogen atom, a halogen atom, a C1 to C4 alkyl group, etc., or R4 is in the 3-position of the phenyl and R3 and R4 join together to form a methylenedioxy group, R5 is a hydrogen atom or a fluorine atom, R6 is an ethylamino group, a dimethylamino group, etc., R7 is a C1 to C4 alkoxy group, and R8 is a C1 to C4 alkoxy group), or a pharmaceutically acceptable salt of this derivative. This is a novel compound that has antagonistic activity against an aruginine-vasopressin V1b receptor.

    摘要翻译: 由式1表示的1,3-二氢-2H-吲哚-2-酮衍生物(其中,R 1为卤素原子,C 1〜C 4烷基等,R 2为氢原子,卤素原子等) ,或R2为吲哚-2-酮的6-位,R 1和R 2连接在一起形成C 3〜C 6亚烷基,R 3为卤素原子,羟基等,R 4为氢原子 卤素原子,C 1〜C 4烷基等,或者R 4在苯基的3-位,R3和R4连接在一起形成亚甲二氧基,R5是氢原子或氟原子,R6是 乙基氨基,二甲基氨基等,R7为C1〜C4烷氧基,R8为C1〜C4烷氧基)或该衍生物的药学上可接受的盐。 这是一种新的化合物,具有对抗葡萄糖酸加压素V1b受体的拮抗作用。